


# The Canadian Clinical Trials Asset Map (CCTAM)

**Jared Rhines,**

Vice President, Scientifics and Strategic Affairs,  
Canada's Research-Based Pharmaceutical Companies (Rx&D)




# The Global Pharmaceutical Market, 2012




Source: Matthias Buente, Stephan Danner, Susanne Weissbäcker, and Christoph Rammé, [“Pharma Emerging Markets 2.0: How Emerging Markets Are Driving the Transformation of the Pharmaceutical Industry.”](#) Booz & Company, 2013.

# Global Patient Recruitment by Region




source: 2012 CMR Factbook

# Clinical Trials by Country: Percent Change from 2005 to 2010




# Clinical Trial Sites by Country: Percent Change from 2005 to 2010



Country by Rank 1 to 16




# Clinical Trial Density & Growth Rate



# Initiatives in the US




TransCelerate BioPharma Initiative



DrugDev.org

# Canada's Strengths in Clinical Trials

- High reputation of researchers, organizations & outputs
  - Diverse population
  - Disease & population-specific networks & health charities
  - National progress on operational barriers
  - Interested public
  - Publically-funded healthcare & provincial funding for health
  - Federal & provincial leadership
- 



# Clinical Trials Summit 2011

- The first ever clinical trial steering committee meeting (Sep 2011)
- 150 experts from Government, Academia, Clinical Sites & Industry
- Topics critical to the Canadian clinical trial environment:
  - Ethics review process
  - Recruitment, patient retention & follow-up (administrative databases, e-records)
  - Cost structure
  - Intellectual Property
  - Administrative (contracts, standard operating procedures, education, training)
  - Future – what strengths can Canada develop that would make a difference in 5-10 years?


# Clinical Trials Action Plan



# Clinical Trials Action Plan

**Vision:** Canada to become a premier country globally for conducting industry led clinical trials (CT)

## Strategic Goals:

1. Establish short & longer term implementation capacity for this action plan & coordination of other CT improvement activities
  2. Improve business operations through better cost, quality, & speed of clinical trial start-up times
  3. Shape a positive future business environment & signal Canada's interest globally with information & incentives
- 

# What is Canadian Clinical Trials Asset Map (CCTAM)?

- Component of Strategic Goal # 3 of Action Plan
- Web-based “living”, easily searchable, interactive database of Canadian clinical research capabilities
- Broad umbrella of stakeholders including Rx&D & member companies, CIHR, DFAIT, Health Canada, Industry Canada, ACAHO, BCCRIN, CTO, N2 and independent research centers


# CCTAM

## Objectives

- Improve capacity for both academia and industry to conduct clinical studies in Canada
- Position Canada globally as an attractive destination for clinical trial investments



# CCTAM's advantages to other database initiatives

- Funded from and based in Canada
  - The only pan-Canadian, fully inclusive initiative leveraging existing asset maps to avoid duplication
  - Comprehensive resource for all aspects of clinical research, i.e. clinical trials sites, research networks, institutional review boards, research organizations and institutions, and individual clinical research experts.
  - Promotes Canadian researchers and sites nationally and internationally
- 


# CCTAM: Design Principles

- Consider from view of both end user's & the sites
- Ensure it meets evolving stakeholder requirements
- Optimize scope & application of the tool




# CCTAM data set details

Comprehensive data set capturing:

- all aspects of clinical research
  - research networks
  - institutional review boards
  - research organizations and institutions, and
  - individual clinical research experts
- 



# CCTAM data collection details

- Phase I – Rx&D member companies data and existing asset maps
  - Phase II – investigators and sites input their own data
  - The future – performance data points and additional data
- 

# Features of CCTAM


- Bilingual
- Comprehensive data set
- Regular updates
- Easy to search
- No cost to contributors to use




# Who Stands to Benefit?

- Academic Research Sites
  - Independent Research Sites
  - Government
  - Industry
  - Academia
  - Canadians
- 

# Progress to Date


- Key audiences & stakeholders identified & engaged
  - Existing asset maps audited to identify unmet needs & potential data sources
  - British Columbia Clinical Research Infrastructure Network's (BCCRIN) Asset Map is being considered as a base framework for CCTAM, among others
  - Initial data points to be included identified
  - Part I of communication strategy developed
- 

# Progress to Date contd.


- Preliminary database development work underway
  - Agreement in principle across Rx&D member companies to contribute data
  - Existing asset maps' data is being extracted
  - GSK and Bayer have already provided data. Other Rx&D member companies will follow shortly.
- 

# CCTAM

## Opportunity for Provincial CT Organizations

- Funding in place for development of a pan-Canadian Asset Map
  - Opportunity to leverage current efforts/infrastructure to “build in” provincial-specific interests
  - Option to “auto-populate” provincial databases in return
  - Pan-Canadian database with full customization for provinces
- 

# Summary

- CCTAM initiative only possible due to the extraordinary participation & commitment of groups & individuals across industries, sectors & geographical locations in Canada
  - Significant progress over the past 18 months in developing the CCTAM
  - Once complete, CCTAM will be a comprehensive one-stop tool for both local & global entities considering Canada as a site for clinical research
  - CCTAM will continue to evolve & develop true to its living tool concept
- 

# For more information...

Please email:

[cctam@canadapharma.org](mailto:cctam@canadapharma.org)

